Back to today’s briefing

Story perspectives

Revolutionary Blood Test Detects 12 Cancers with 99% Accuracy

4/26/2025

49 11

Summary

miONCO-Dx Revolutionizes Detection

The miONCO-Dx test is transforming cancer detection with its groundbreaking, non-invasive approach, identifying up to 12 prevalent cancers, including lung and breast, with over 99% accuracy. By analyzing just 10 drops of blood through advanced AI technology, it promises to enhance early diagnosis and boost survival rates. A UK NHS trial will engage 8,000 patients to evaluate its true potential.

Summary

Mursla Bio Innovates Diagnostics

Mursla Bio's EvoLiver Test has received FDA Breakthrough Device Designation, revolutionizing liver cancer detection. By extracting liver-specific extracellular vesicles from blood, it boasts nearly three times the sensitivity of standard ultrasounds. This groundbreaking, non-invasive approach promises to boost early diagnosis rates and lower healthcare expenses, tackling the critical demand for better liver cancer diagnostics.

1 of 2

miONCO-Dx Revolutionizes Detection

The miONCO-Dx test is transforming cancer detection with its groundbreaking, non-invasive approach, identifying up to 12 prevalent cancers, including lung and breast, with over 99% accuracy. By analyzing just 10 drops of blood through advanced AI technology, it promises to enhance early diagnosis and boost survival rates. A UK NHS trial will engage 8,000 patients to evaluate its true potential.

1 / 2